

CLEC12A/MICL/CLL-1

Catalog # PVGS1837

Product Information

| | |
|-------------------------------------|---|
| Primary Accession Species | Q5QGZ9-2 Human |
| Sequence | His65-Ala265 |
| Purity | > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
| Endotoxin Level | Less than 1EU per μ g by the LAL method. |
| Biological Activity | Immobilized Anti-CLEC12A Antibody, hFc Tag at 1 μ g/ml (100 μ l/Well) on the plate can bind CLEC12A/MICL/CLL-1 hFc Chimera[Biotin], Avi, Human (Cat.No.: Z03960) |
| Expression System | HEK293 |
| Theoretical Molecular Weight | 51.7 kDa |
| Formulation | Lyophilized from a 0.22 μ m filtered solution in PBS, (pH 7.4). |
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O more than 100 μ g/ml. |
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |

Additional Information

| | |
|--------------------------|--|
| Target Background | CLEC12A, also known as CLL-1 is inhibitory C-type lectin-like receptor with ITIM motif. It can associate with signaling phosphatases SHP-1 and SHP-2. CLEC12A is a potential target due to its high expression in acute myeloid leukemia (AML) cells. And there are various therapeutic approaches using CLEC12A as a target for AML, such as CD3/ CLEC12A antibody. It can recruit unstimulated primary T cells against cancer cells with CLL-1 on the surface. |
|--------------------------|--|

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.